Astrazeneca Pharma India Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|
| Revenue | 537.55 | 496.63 | 448.27 |
| Operating Expense | 445.56 | 399.79 | 396.85 |
| Net Profit | 55.83 | 58.25 | 30.85 |
| Net Profit Margin | 10.39 | 11.73 | 6.88 |
| Earning Per Share | 22.33 | 23.30 | 12.34 |
| EBIDTA | 95.22 | 99.54 | 52.42 |
| Effective Tax Rate | 24.02 | 23.67 | 23.67 |
| Particulars | Jun 2025 |
|---|---|
| Revenue | 537.55 |
| Operating Expense | 445.56 |
| Net Profit | 55.83 |
| Net Profit Margin | 10.39 |
| Earning Per Share | 22.33 |
| EBIDTA | 95.22 |
| Effective Tax Rate | 24.02 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Total Revenue Annual | 1,716.29 | 1,295.53 | 1,002.97 |
| Operating Expenses Annual | 1,462.32 | 1,111.08 | 837.85 |
| Operating Profit Annual | 197.81 | 235.68 | 150.99 |
| Interest Annual | 1.46 | 1.20 | 0.63 |
| Depreciation | 38.54 | 14.81 | 12.47 |
| Net Profit Annual | 115.74 | 161.51 | 99.29 |
| Tax Annual | 40.62 | 58.03 | 34.81 |
| Particulars | Mar 2025 |
|---|---|
| Total Revenue Annual | 1,716.29 |
| Operating Expenses Annual | 1,462.32 |
| Operating Profit Annual | 197.81 |
| Interest Annual | 1.46 |
| Depreciation | 38.54 |
| Net Profit Annual | 115.74 |
| Tax Annual | 40.62 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Cash Flow at the Beginning | 505.57 | 500.34 | 448.42 |
| Cash Flow from Operations | 65.36 | 27.87 | 58.29 |
| Cash Flow from Investing | 30.80 | 21.74 | 18.11 |
| Cash Flow from Financing | -65.59 | -44.38 | -24.48 |
| Cash Flow at the End | 536.14 | 505.57 | 500.34 |
| Particulars | Mar 2025 |
|---|---|
| Cash Flow at the Beginning | 505.57 |
| Cash Flow from Operations | 65.36 |
| Cash Flow from Investing | 30.80 |
| Cash Flow from Financing | -65.59 |
| Cash Flow at the End | 536.14 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| PBDIT Margin (%) | 17.15 | 18.19 | 18.82 |
| PBIT Margin (%) | 14.82 | 17.04 | 17.20 |
| PBT Margin (%) | 4.67 | 2.84 | -10.09 |
| Net PROFIT Margin (%) | 6.74 | 12.47 | 9.90 |
| Return On Networth / Equity (%) | 23.63 | 24.84 | 22.95 |
| Return On Networth /Employed (%) | 32.94 | 33.26 | 30.47 |
| Return On Assets (%) | 14.97 | 24.31 | 17.52 |
| Total Debt / Equity (X) | 0.03 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 2.22 | 1.95 | 1.77 |
| Particulars | Mar 2025 |
|---|---|
| PBDIT Margin (%) | 17.15 |
| PBIT Margin (%) | 14.82 |
| PBT Margin (%) | 4.67 |
| Net PROFIT Margin (%) | 6.74 |
| Return On Networth / Equity (%) | 23.63 |
| Return On Networth /Employed (%) | 32.94 |
| Return On Assets (%) | 14.97 |
| Total Debt / Equity (X) | 0.03 |
| Asset Turnover Ratio (%) | 2.22 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Fixed Assets Annual | 64.24 | 66.68 | 68.86 |
| Total Current Assets Annual | 1,342.35 | 932.71 | 835.47 |
| Non Current Assets Annual | 175.77 | 145.32 | 149.40 |
| Total Shareholders Funds Annual | 770.35 | 711.92 | 588.69 |
| Total Assets Annual | 1,518.12 | 1,078.03 | 984.87 |
| Particulars | Mar 2025 |
|---|---|
| Fixed Assets Annual | 64.24 |
| Total Current Assets Annual | 1,342.35 |
| Non Current Assets Annual | 175.77 |
| Total Shareholders Funds Annual | 770.35 |
| Total Assets Annual | 1,518.12 |
No Data Availabe
